Effect of the Association of Standardized Extracts of Cannabis sativa L. (CBD) with Bixa orellana L. (Chronic® and Chronic In®) on Pain Models in Wistar Rats

The present study aimed to evaluate the potential synergy between pharmaceutical formulations containing Bixa orellana L. (granulated – CHR OR and injectable nanodispersion – CHR IN) in conjunction with a cannabidiol (CBD)-rich extract of Cannabis sativa L. (CSE) on experimental pain models in Wistar rats, including acetic acid-induced writhing, formalin, hot plate, and cold-water tail withdrawal tests. Chemical analyses by chromatography confirmed that the oil from B. orellana is rich in δ-tocotrienol (72.0 ± 1.0%), while the oil from Cannabis sativa highlighted the presence of cannabidiol (CBD). The results from the experimental pain tests indicated that the combined administration of formulations containing Bixa orellana and C. sativa, such as the granulated CHR OR (400 mg/kg, orally) with CSE (40 mg/kg, orally) or the nanodispersion CHR In (10 mg/kg, intramuscularly) with CSE (40 mg/kg, orally), demonstrated significant results (p < 0.001) in pain reduction. Although the formulations containing Bixa orellana extract showed statistical significance in the tests when used in isolation, their effects were inferior compared to the combined use with CSE or the isolated use of CSE. These findings suggest that combining formulations containing extracts of these plant species may represent a viable therapeutic option, considering the synergistic action in reducing pain under the experimental conditions employed. These results imply that combining the phytocomplexes present in B. orellana and C. sativa may be a promising approach for pain treatment.